NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
June 28, 2024 16:04 ET
|
NurExone Biologic Inc
Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
June 21, 2024 16:04 ET
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
June 11, 2024 08:44 ET
|
NurExone Biologic Inc
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
June 04, 2024 16:40 ET
|
NurExone Biologic Inc
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
May 29, 2024 08:35 ET
|
NurExone Biologic Inc
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
May 17, 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Welcomes Biopharma Executive Dr. Ram Petter to Drive Strategic Collaborations
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
April 25, 2024 08:35 ET
|
NurExone Biologic Inc
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
April 19, 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
April 02, 2024 08:31 ET
|
NurExone Biologic Inc
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
March 27, 2024 17:05 ET
|
NurExone Biologic Inc
Gross Proceeds close of $4M CAD Generated for NurExone from Warrants Exercise